Identification of an Imidazopyridine-based Compound as an Oral Selective Estrogen Receptor Degrader for Breast Cancer Therapy.
Pan M, Solozobova V, Kuznik NC, Jung N, Gräßle S, Gourain V, Heneka YM, Cramer von Clausbruch CA, Fuhr O, Munuganti RSN, Maddalo D, Blattner C, Neeb A, Sharp A, Cato L, Weiss C, Jeselsohn RM, Orian-Rousseau V, Bräse S, Cato ACB.
Pan M, et al. Among authors: blattner c.
Cancer Res Commun. 2023 Jul 27;3(7):1378-1396. doi: 10.1158/2767-9764.CRC-23-0111. eCollection 2023 Jul.
Cancer Res Commun. 2023.
PMID: 37520743
Free PMC article.